Research progress of anti-vascular endothelial growth factor drugs in the treatment of diabetes retinopathy
Diabetic retinopathy(DR)is the most serious microvascular complication of the eyes in diabetic patients,which seriously affects the visual function of patients,and it is also the leading cause of blindness in diabetic patients worldwide.Vascular endothelial growth factor(VEGF)plays a key role in the pathogenesis of DR and is the main angiogenic factor that induces retinal neovascularization.There are currently 7 family members,including VEGF-A,VEGF-B,VEGF-C,VEGF-D,VEGF-E,VEGF-F and placental growth factor(PLGF),which trigger a series of physiological activities by acti-vating tyrosine kinase receptors,namely vascular endothelial growth factor receptors(VEGFR)-1 and VEGFR-2,and fur-ther accelerate the progression of DR.Intravitreal injection of anti-VEGF drugs is currently an effective measure for the treatment of DR,and by specific binding to VEGF,retinal neovascularization and reduction of macular edema can be signif-icantly resolved.Commonly used anti-VEGF drugs include bevacizumab,ranibizumab,compacept,aflibercept and so on.However,anti-VEGF drugs have a short half-life and need to be injected again after a certain period of time,and the safety of long-term repeated application still needs further study.The research progress of anti-VEGF in the treatment of DR has been reviewed.
万方数据
维普
